Of Genetic Medicines
We are boldly innovating to unlock the full potential of genetic medicines for large market diseases. We harness the power of directed evolution to invent customized and enhanced vectors for use in our transformative products for patients.
Driven by our innovative vector platform and efficient product design and development engine, we are inventing and developing genetic medicines with proprietary customized vectors that are optimized for the specific diseases we treat. Our clinical product development programs are initially focused in ophthalmology, pulmonology and cardiology.
We partner with patient organizations, patients, their families and their physicians to better understand their challenges and unmet needs. We integrate this knowledge so we can continuously develop and improve our products as we strive to provide transformative benefit for patients and potentially even cures.
Our exceptional team is committed to a culture that empowers the highest degree of innovation, teamwork, preparation and execution excellence. We value and cultivate internal and external collaborations. We seek to build diverse teams, capabilities, product pipelines and business models.
/wp-content/uploads/4dmt_logo.svg
0
0
Erik Allison
/wp-content/uploads/4dmt_logo.svg
Erik Allison2025-01-14 13:05:052025-01-14 13:06:034D-150 for DME moving to phase 3 trial following positive interim data
/wp-content/uploads/4dmt_logo.svg
0
0
David Anderson
/wp-content/uploads/4dmt_logo.svg
David Anderson2024-10-15 15:39:592024-10-15 15:39:59VIDEO: Intravitreally administered 4D-150 shows 90% reduction in wet AMD treatment burden
/wp-content/uploads/4dmt_logo.svg
0
0
Erik Allison
/wp-content/uploads/4dmt_logo.svg
Erik Allison2024-10-02 13:09:102024-10-02 13:09:10Fresh data intensifies race for a major gene therapy target
/wp-content/uploads/4dmt_logo.svg
0
0
Erik Allison
/wp-content/uploads/4dmt_logo.svg
Erik Allison2024-10-02 13:08:262024-10-02 13:08:264DMT’s gene therapy reduced need for standard-of-care injections to treat age-associated vision loss
/wp-content/uploads/4dmt_logo.svg
0
0
Erik Allison
/wp-content/uploads/4dmt_logo.svg
Erik Allison2024-10-02 13:07:272024-10-02 13:07:27In race to make gene therapy for age-related blindness, 4D Molecular announces positive results
/wp-content/uploads/4dmt_logo.svg
0
0
Erik Allison
/wp-content/uploads/4dmt_logo.svg
Erik Allison2024-08-06 16:13:062024-08-06 16:13:44East Bay biotech targeting eye diseases makes 3 critical hires
/wp-content/uploads/4dmt_logo.svg
0
0
Erik Allison
/wp-content/uploads/4dmt_logo.svg
Erik Allison2024-08-06 16:12:342024-08-06 16:12:344D Molecular Therapeutics’ Wet AMD Gene Therapy 4D-150 Reduces Need for antiVEGF Injections
/wp-content/uploads/4dmt_logo.svg
0
0
Erik Allison
/wp-content/uploads/4dmt_logo.svg
Erik Allison2024-08-06 16:11:382024-08-06 16:11:384D Molecular Therapeutics announces positive initial interim 24-week landmark data from population extension cohort of PRISM phase 2 clinical trial of 4D-150
https://4dmoleculartherapeutics.com/wp-content/uploads/jennifer-taylor-cousar-md-mscs-discusses-4d-710.webp
541
964
David Anderson
/wp-content/uploads/4dmt_logo.svg
David Anderson2024-07-10 17:17:262024-07-10 17:20:53VIDEO: Jennifer Taylor-Cousar, MD, MSCS, discusses 4D-710, 4DMT’s gene therapy candidate for treating cystic fibrosis
https://4dmoleculartherapeutics.com/wp-content/uploads/Healio.jpg
340
454
Erik Allison
/wp-content/uploads/4dmt_logo.svg
Erik Allison2024-06-21 12:30:202024-06-21 14:10:01VIDEO: ‘Excellent’ anatomic, vision control seen with 4D-150 at 24 weeks
/wp-content/uploads/4dmt_logo.svg
0
0
Erik Allison
/wp-content/uploads/4dmt_logo.svg
Erik Allison2024-05-07 11:27:412024-05-07 11:27:41Using Directed Evolution to Develop New Vectors for Genetic Medicines
/wp-content/uploads/4dmt_logo.svg
0
0
Erik Allison
/wp-content/uploads/4dmt_logo.svg
Erik Allison2024-04-04 15:13:292024-04-04 15:13:29Vectorized biologics: are patients and payers ready to swap biologics for gene therapies?
/wp-content/uploads/4dmt_logo.svg
0
0
Erik Allison
/wp-content/uploads/4dmt_logo.svg
Erik Allison2024-02-08 17:13:302024-02-08 17:13:304D Molecular soars as mid-stage data for eye disease therapy ‘checks all boxes’
/wp-content/uploads/4dmt_logo.svg
0
0
Erik Allison
/wp-content/uploads/4dmt_logo.svg
Erik Allison2024-02-08 15:27:532024-02-08 15:27:534DMT links gene therapy to drop in Eylea injections, fueling plans to enter phase 3
/wp-content/uploads/4dmt_logo.svg
0
0
Erik Allison
/wp-content/uploads/4dmt_logo.svg
Erik Allison2024-02-08 15:25:212024-02-08 15:28:314D Molecular Therapeutics’ gene therapy cuts Eylea use in wet AMD patients, biotech divulges plans for pivotal studies
/wp-content/uploads/4dmt_logo.svg
0
0
Erik Allison
/wp-content/uploads/4dmt_logo.svg
Erik Allison2024-02-08 15:23:532024-02-08 15:23:534DMT shares pipeline progress and the appointment of new CSO and SAB board members
/wp-content/uploads/4dmt_logo.svg
0
0
Erik Allison
/wp-content/uploads/4dmt_logo.svg
Erik Allison2024-01-11 15:46:452024-01-11 15:46:454DMT and Arbor Biotechnologies Partnership to Develop Genetic Medicines for CNS Diseases
/wp-content/uploads/4dmt_logo.svg
0
0
Erik Allison
/wp-content/uploads/4dmt_logo.svg
Erik Allison2024-01-11 15:45:242024-01-11 15:45:42J&J’s new partnership with Elektrofi; Enyo raises €39M; Arrowhead’s $450M offering
/wp-content/uploads/4dmt_logo.svg
0
0
Erik Allison
/wp-content/uploads/4dmt_logo.svg
Erik Allison2024-01-11 15:43:182024-01-11 15:43:184D-710 leads to quality of life gains for CF patients in clinical trial
/wp-content/uploads/4dmt_logo.svg
0
0
Erik Allison
/wp-content/uploads/4dmt_logo.svg
Erik Allison2024-01-11 15:41:172024-01-11 16:22:49Positive Clinical Trial Results and Future Prospects Reinforce Buy Rating for 4D Molecular Therapeutics: An Analysis by Geulah Livshits
/wp-content/uploads/4dmt_logo.svg
0
0
Erik Allison
/wp-content/uploads/4dmt_logo.svg
Erik Allison2024-01-11 15:39:312024-01-11 15:55:064DMT: First patient enrolled in 4D-150 Phase 2 SPECTRA, PRIS clinical trials
/wp-content/uploads/4dmt_logo.svg
0
0
Erik Allison
/wp-content/uploads/4dmt_logo.svg
Erik Allison2023-09-22 08:00:252023-09-27 10:56:46Astellas eyes rare ophthalmology, licensing 4DMT’s viral vector for gene therapy for up to $962M
/wp-content/uploads/4dmt_logo.svg
0
0
Erik Allison
/wp-content/uploads/4dmt_logo.svg
Erik Allison2023-09-21 08:00:332023-09-26 17:39:48Astellas paves backloaded biobucks deal to test 4DMT’s eye disease gene therapy vector
/wp-content/uploads/4dmt_logo.svg
0
0
Erik Allison
/wp-content/uploads/4dmt_logo.svg
Erik Allison2023-09-20 08:00:592023-09-26 17:40:534DMT’s inhalable gene therapy for cystic fibrosis shows early positive signs in tiny group of patients
/wp-content/uploads/4dmt_logo.svg
0
0
Erik Allison
/wp-content/uploads/4dmt_logo.svg
Erik Allison2023-09-19 08:00:322023-09-26 17:41:08Aerow hits the mark for 4D Molecular
/wp-content/uploads/4dmt_logo.svg
0
0
Erik Allison
/wp-content/uploads/4dmt_logo.svg
Erik Allison2023-09-18 08:00:472023-09-26 17:41:19ReCode, Vertex and 4DMT Seek to Help Untreated Cystic Fibrosis Patients
/wp-content/uploads/4dmt_logo.svg
0
0
Erik Allison
/wp-content/uploads/4dmt_logo.svg
Erik Allison2023-09-17 08:00:562023-09-26 17:41:385 Gene Therapy Companies That May Transform the Medical Industry
/wp-content/uploads/4dmt_logo.svg
0
0
Erik Allison
/wp-content/uploads/4dmt_logo.svg
Erik Allison2023-09-16 08:00:092023-09-26 17:41:504D Molecular Therapeutics acquires eye disease asset from Fortress Biotech subsidiary
/wp-content/uploads/4dmt_logo.svg
0
0
Erik Allison
/wp-content/uploads/4dmt_logo.svg
Erik Allison2023-09-15 08:00:002023-09-26 17:42:05They were the 10% left out of life-changing treatments. Now these cystic fibrosis patients may finally get help
/wp-content/uploads/4dmt_logo.svg
0
0
Erik Allison
/wp-content/uploads/4dmt_logo.svg
Erik Allison2023-09-14 08:00:582023-09-26 17:42:18#NACFC2022 – 4D-710 Safe, Restores CFTR Lung Production in 3 Patients